Ro-052921

Ro-052921

SCHEMBL1365706

O=C1CN=C(c2ccccc2)c2ccccc2N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 6/20 1.00
GABRA5 P31644 6/20 1.00
GABRA3 P34903 6/20 1.00
GABRA2 P47869 6/20 1.00
GABRB2 P47870 6/20 1.00
GABRG2 P18507 4/20 1.00
GABRB3 P28472 4/20 1.00
PDE4D Q08499 2/20 0.69
CNR1 P21554 1/20 0.69
NTSR1 P30989 1/20 0.69
OPRK1 P41145 1/20 0.69
LMNA P02545 2/20 0.63
HPGD P15428 1/20 0.63
KMT2A Q03164 1/20 0.56
GABRP O00591 2/20 0.52
GABRD O14764 2/20 0.52
GABRB1 P18505 2/20 0.52
GABRA4 P48169 2/20 0.52
GABRE P78334 2/20 0.52
GABRA6 Q16445 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ro-052921 SCHEMBL29979594 1.00 GABRA1 (1.00) GABRA1GABRA5GABRA3GABRA2GABRB2
SCHEMBL11543658 0.88 GABRA1 (0.78) GABRA1GABRA5GABRA3GABRA2GABRB2
SCHEMBL2615411 0.88 GABRA1 (0.78) GABRA1GABRA5GABRA3GABRA2GABRB2
SCHEMBL2615408 0.88 GABRA1 (0.78) GABRA1GABRA5GABRA3GABRA2GABRB2
Ro-052921 SCHEMBL6529437 0.84 GABRA1 (0.71) GABRA1GABRA5GABRA3GABRA2GABRB2
SCHEMBL7832057 0.84 GABRA1 (0.72) GABRA1GABRA5GABRA3GABRA2GABRB2
SCHEMBL27587130 0.84 GABRA1 (0.72) GABRA1GABRA5GABRA3GABRA2GABRB2
SCHEMBL5356267 0.84 GABRA1 (0.72) GABRA1GABRA5GABRA3GABRA2GABRB2
SCHEMBL8726318 0.84 GABRA1 (0.72) GABRA1GABRA5GABRA3GABRA2GABRB2
Ro-052921 SCHEMBL30286762 0.84 GABRA1 (0.72) GABRA1GABRA5GABRA3GABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116075516-A Benzodiazepine derivatives useful for the treatment of respiratory syncytial virus infection 辉瑞大药厂 2023-05-05 CN claimed
EP-4017856-A1 PHARMACEUTICAL COMPOUNDS Reviral Limited (GB) 2022-06-29 EP claimed
US-20160083355-A1 COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION COMMISSARIAT ENERGIE ATOMIQUE (FR) 2016-03-24 US claimed
US-20140073633-A1 INHIBITORS OF THE SHIGA TOXINS TRAFFICKING THROUGH THE RETROGRADE PATHWAY COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT. (FR) 2014-03-13 US claimed
US-20120283249-A1 Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2012-11-08 US claimed
US-20110201601-A1 INHIBITORS OF THE SHIGA TOXINS TRAFFICKING THROUGH THE RETROGRADE PATHWAY COMMISSAR. A L'ENERG. ATOM. ET AUX ENERG. ALTERN. (FR) 2011-08-18 US claimed
EP-2296757-A2 INHIBITORS OF THE SHIGA TOXINS TRAFFICKING THROUGH THE RETROGRADE PATHWAY Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) 2011-03-23 EP claimed
EP-2145873-A1 New compounds with activity that protects against the action of toxins and viruses in intracellular action mode COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2010-01-20 EP claimed
WO-2009153665-A2 INHIBITORS OF THE SHIGA TOXINS TRAFFICKING THROUGH THE RETROGRADE PATHWAY COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2009-12-23 WO claimed
US-20060217362-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2006-09-28 US claimed
WO-2006071775-A2 NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM ELAN PHARMACEUTICALS, INC. (US) 2006-07-06 WO claimed
CN-1399634-A Hydroxyalkanoyl aminolactams and related structure as inhibitors of A beta protein production BRISTOL MYERS SQUIBB PHARMA IN (US) 2003-02-26 CN claimed
CN-1242007-A Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising such compounds, and methods of inhibiting beta amyloid peptide release and/or its synthesis using such compounds ELAND PHARMACEUTICAL CORP (US) 2000-01-19 CN claimed
US-20250313537-A1 BENZODIAZEPINE ANALOGS AND METHODS OF USE IN TREATING CANCER UNIVERSITY OF CINCINNATI (US) 2025-10-09 US disclosed
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-05-13 US disclosed
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-04-08 US disclosed
US-3996209-A Process for preparing benzodiazepines HOFFMANN-LA ROCHE INC. (US) 1976-12-07 US disclosed
US-3992408-A CHEMICAL INTERMEDIATES THE UPJOHN COMPANY (US) 1976-11-16 US disclosed
US-3987052-A SEDATIVES, TRANQUILIZERS, MUSCLE RELAXANTS THE UPJOHN COMPANY (US) 1976-10-19 US disclosed
US-3946032-A Acetal derivatives of 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine-1-carboxaldehyde CIBA-GEIGY CORPORATION (US) 1976-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283249-A1 Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action HAVCR2, MAVS, ANTXR2 GABRA1 40/4885GABRA5 19/4885GABRA3 42/4885
US-20140073633-A1 INHIBITORS OF THE SHIGA TOXINS TRAFFICKING THROUGH THE RETROGRADE PATHWAY SLC47A2, GOLT1B, SLC47A1 GABRA1 1128/4885GABRA5 789/4885GABRA3 1137/4885
US-20160083355-A1 COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION HAVCR2, MAVS, ANTXR2 GABRA1 20/4885GABRA5 6/4885GABRA3 21/4885
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 GABRA1 2/4885GABRA5 1/4885GABRA3 10/4885
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ACE, ACE2, SPCS3 GABRA1 2645/4885GABRA5 1940/4885GABRA3 2714/4885
US-20110201601-A1 INHIBITORS OF THE SHIGA TOXINS TRAFFICKING THROUGH THE RETROGRADE PATHWAY SLC47A2, GOLT1B, SLC47A1 GABRA1 1128/4885GABRA5 789/4885GABRA3 1137/4885
US-20060217362-A1 Novel compounds useful for bradykinin B1 receptor antagonism BDKRB1, BDKRB2, NPBWR1 GABRA1 194/4885GABRA5 490/4885GABRA3 396/4885
US-20250313537-A1 BENZODIAZEPINE ANALOGS AND METHODS OF USE IN TREATING CANCER GABRA3, GABRB3, GABRA4 GABRA1 6/4885GABRA5 5/4885GABRA3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.